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Regenerating or replacing bone, chondral and osteochondral defects, is an active field in tissue engineering.
A general strategy is to use a temporary scaffold in which cells are seeded onto the scaffold prior to
implantation or attracted into the scaffold from surrounding tissues in the implantation site to form the
desired tissue. Several biomaterials have been used for the fabrication of scaffolds, including
polycaprolactone (PCL) which is often used for musculoskeletal tissue engineering. The effect of the PCL
scaffold architecture on the cell behavior has been investigated. However, the mechanical properties of
the bulk material were not taken into account in these studies. PCL is available in a range of molecular
weights, resulting in a range of bulk mechanical properties. Since bulk material stiffness is able to direct
cell differentiation, it is likely that the molecular weight of PCL may influence cell behavior. Here, we
investigated the bulk material properties of both low and high molecular weight PCL scaffolds fabricated
through additive manufacturing. The low molecular weight PCL showed a lower bulk material stiffness.
During in vitro cell culture, this resulted in a stronger tendency for hypertrophic chondrogenic
differentiation compared to the high molecular weight PCL. This study shows that apart from the
polymer chemistry and scaffold architecture, the bulk mechanical properties of the polymer used is an
important parameter in scaffold fabrication. This is an important finding for the optimization of
osteochondral tissue engineering.Introduction
Major research areas in tissue engineering are the treatments of
bone, chondral and osteochondral defects. The advent of
defects or degeneration of these tissues can be due to traumatic
injury, congenital, hereditary or autoimmune diseases.1 The
impact of skeletal defects on daily life can be severe and some
sort of intervention is oen necessary. In some cases, the
spontaneous healing capacity of skeletal tissues is not sufficient
and temporary, or permanent, help is needed to support tissue
healing. Several tissue engineering strategies exist aiming at
restoring or replacing the malfunctioning tissue.2–4
One of these strategies is using a temporary structure, a
scaffold, in which cells are seeded and implanted, or to which
cells are attracted upon implantation. The scaffold has to elicit a
desirable response and should therefore possess a number of
properties in order to facilitate a proper functioning.5–7 For
instance, the scaffold should allow nutrient exchange and waste
removal through interconnected pores, the biomaterial shouldInstitute for Biomedical Technology and
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be biocompatible and biodegradable, while the mechanical
properties of the scaffold should ideally mimic the mechanical
properties of the native tissue and simultaneously shield the
forming tissue from excessive mechanical loading. Further-
more, themechanical properties of the scaffold could be used to
elicit a specic cellular response when biophysically loaded.
The properties of the scaffold should be tailored to match the
formation of the new tissue in the scaffold.8 A ceramic, a
natural-, or a synthetic polymer is oen used to fabricate scaf-
folds for tissue engineering purposes. Advantages of ceramic
and natural polymers are that their intrinsic properties can
elicit cellular responses on their own. However, processing of
these materials to fabricate scaffolds with controlled pore
shapes and porosity is oen more difficult compared to
synthetic polymers.5,9,10 Although synthetic polymers in general
don't possess intrinsic properties to elicit cellular response, the
ability to tailor the material to display desirable properties
makes them very interesting. Due to this, synthetic polymers
like polycaprolactone (PCL), poly lactic acid (PLA) and poly
glycolic acid (PGA) are oen used as the biomaterial for scaf-
folds.7,11–14 All of these biodegradable synthetic polymers have
found their way into clinical applications and are well described
in literature. Especially PCL has a long track record in
biomedical applications, as also well described in a review by
Woodruff and Hutmacher.15 In this study, we use PCL scaffolds































































































View Article Onlinetechnology allows for the control of the scaffold geometry, and
thereby enables the fabrication of patient specic scaffolds. Apart
from that, the scaffold internal architecture can be controlled
and reproduced. As such, possible effect of the fabrication tech-
nique used on cell behaviour can be eliminated.16,17
Because PCL is such a common material, PCL of different
molecular weights can be obtained. The surface chemistry and
topography is expected to be the same when obtaining PCL
scaffolds through the same production technique. However, the
bulk stiffness of the different molecular weights will be
different. From literature, it is known that the bulk material
stiffness can inuence cell behaviour.18–20 In these studies,
hydrogels with a stiffness in the range of 1–100 kPa were
generally used as biomaterials. Cells were either cultured on 2D
hydrogels,21 coated with collagen type I,19,20 or encapsulated in
the hydrogel.22,23 To the authors' knowledge, the effect of
mechanical properties of stiffer polymers, such as PCL, on cells
has not been investigated. Additionally, the effect of bulk
material stiffness on cells in an open porous 3D scaffold is not
known. We hypothesize that by using PCL with different
molecular weights, a difference in behaviour of mesenchymal
stromal cells can be observed.Materials and methods
Scaffold fabrication
Scaffolds were fabricated by a BioScaffolder (SYSeng, Germany),
as previously described.24 Briey, granules of either low PCL (Mw
14.000, Sigma) or high PCL (Mw 65.000, Sigma) were inserted in
the cartridge of the machine and heated to 60–65 C for low PCL
and to 125–130 C for high PCL. An applied nitrogen pressure of
5 bar and an auger screw system rotating at 200 RPM extruded
the molten polymer through a 250 mm diameter needle (DL
technology) on a stationary platform. Scaffolds were fabricated
through a layer-by-layer deposition, in which the angle between
layers, ber spacing and layer thickness can be set while the
ber diameter depends on the needle size chosen. Scaffold
blocks of 30  30  2.1 mm were created with a ber diameter
of 175–200 mm, a layer thickness of 150 mm, a ber spacing of
1000 mm and 90 angle between layers. Cylindrical scaffolds of
8 mm in diameter were obtained by using a biopsy puncher
(Miltex). The actual ber spacing and ber diameter were
measured with ImageJ. For this, stereomicroscope images were
loaded and measurements were performed at random locations
(3 samples, 5 measurements per sample).Mechanical characterization of low and high PCL
Solid blocks of low and high PCL were obtained through
compression molding to determine the stiffness of the bulk
material. Polymer granules of either low or high PCL were
placed in an open, heated mold cavity, 50 mm diameter and
2 mm high. Aer closing the mold with a plug, pressure was
applied and the mold was heated until the polymer reached the
molten phase. The mold was pressurized and heated for
5 minutes, aer which the samples were cooled to room
temperature. Three cylindrical plugs of 6 mm diameter wereThis journal is © The Royal Society of Chemistry 2015punched from the blocks and used for determination of the
bulk material stiffness. An unconned compression test was
performed with a Zwick Z050. A compression of 5% strain per
minute to a maximum of 15% strain was applied. Stresses at 4%
and 8% strain were used to calculate the stiffness.
Cell culture
Bone marrow aspirates were obtained from patients aer written
informed consent. hMSCs were isolated and proliferated as
described previously.25 Basic medium consisted of a-MEM
(Gibco) supplemented with 10% FBS (Lonza), 0.2 mM L-ascorbic
acid (Sigma), 2 mM L-glutamine (Gibco), 100 U mL1 penicillin
(Life Technologies) and 100 mg mL1 streptomycin (Life Tech-
nologies). Proliferation medium was basic medium supple-
mented with 1 ng mL1 bFGF (Instruchemie). Osteogenic
differentiation medium consisted of basic medium supple-
mented with 10 nM dexamethasone (Sigma). Chondrogenic
differentiationmedium consisted of high glucose D-MEM (Gibco)
supplemented with 50 mg mL1 ITS pre-mix (BD biosciences), 50
mg mL1 L-ascorbic acid (Sigma), 100 mg mL1 sodium pyruvate
(Sigma), 100 U mL1 penicillin (Invitrogen) and 100 mg mL1
streptomycin (Invitrogen), 10 ngmL1 TGF-b3 (R&D systems) and
0.1 nM dexamethasone, which were freshly added every time that
mediumwas changed. Cells were grown up to 80–90% conuency
at 37 C in a humidied atmosphere with 5% CO2. Passage 3 cells
were used for all experiments.
Cell culture on scaffolds
Scaffolds were sterilized by immersion in 70% ethanol, twice for
at least 15 minutes, and were subsequently washed with PBS.
Aerwards, the sterile scaffolds were immersed in a 1 mg mL1
rat tail collagen type I (BD biosciences) solution overnight in a
cell culture incubator. Scaffolds were washed with PBS and dried
with the aspiration pump shortly before seeding 500.000 hMSCs
per scaffold in 65 mL proliferation medium. hMSCs for chon-
drogenic differentiation were pre-incubated with 0.3 mg mL1
bronectin (Invitrogen) for 15 minutes before seeding. Aer
seeding, cells were allowed to attach to the scaffold surface for 4
h before adding proliferation medium to 2 mL per scaffold. All
scaffolds were cultured in proliferationmedium for 7 days before
changing to either basic, osteogenic or chondrogenic differen-
tiationmedium. Scaffolds were removed from cell culture aer 7,
14 and 28 days of culture in differentiation media. At each time
point, 3 scaffolds were collected for biochemical analysis, 1 for
histology and 1 for microscopy. Every other day the medium was
refreshed. The cell seeded scaffolds were placed in an incubator
at 37 C in a humidied atmosphere with 5% CO2.
DNA assay
Cell cultured scaffolds (N ¼ 3) were cut in half for either a.u.
ALP/mg DNA quantication or mg GAG/mg DNA quantication.
Each half was cut in as small pieces as possible and subjected to
a cycle of freeze-thawing 5 times before analysis. Total DNA
content was determined, on either lysate, following the manu-
facturer's protocol (CyQuant Cell proliferation assay kit). ALP
and GAG were corrected by their total DNA content.RSC Adv., 2015, 5, 54510–54516 | 54511
Fig. 1 Methylene blue staining of hMSC cultured on high PCL (A–C,
G–I and M–O) and low PCL (D–F, J–L and P–R) in basic (A–F), oste-
ogenic (G–L) and chondrogenic (M–R) differentiation medium (scale































































































View Article OnlineALP assay
Cell lysis buffer (0.1 M KH2PO4, 0.1 M K2HPO4, 0.1% Triton
X-100, pH 7.8) was added to the cut samples and incubated for
1 hour at room temperature before ALP or DNA quantication.
ALP activity was quantied from the lysate according to the
manufacturer's protocol (CDP-star Chemiluminescent substrate
kit, Roche) with a VICTOR plate reader (Perkin-Elmer).
GAG assay
The other half of the cell cultured scaffold was digested in 1
mgmL1 proteinase K (Sigma) in Tris/EDTA (pH 7.6) containing
18.5 mg mL1 iodoacetamine (Sigma) and 1 mg mL1 pepstatin A
(Sigma) for 16 hours at 56 C. Sulphated GAG content was
spectrophotometrically determined immediately aer adding
9-dimethylmethylene blue dye (DMMB, 3.04 g L1 glycine,
2.37 g L1 of NaCl, pH ¼ 3) at an absorbance of 525 nm in a
Multiskan Go (Perkin-Elmer). The amount of GAG was deter-
mined using a calibration curve of chondroitin sulphate.
Methylene blue and ALP staining
Cell seeded scaffolds were washed with PBS and xated by 10%
neutral buffered formalin for 1 hour. Scaffolds were cut in half
and one part was used for methylene blue and the other for ALP
staining. A drop of 1% methylene blue solution was applied to
the scaffold for one minute. The stained scaffolds were washed
with demineralized water until there was no more discolouring
of the water. Samples were imaged with a Nikon SMZ-10A
stereomicroscope equipped with a Sony 3CCD camera.
ALP staining was conducted with the Leukocyte Alkaline
Phosphatase kit (Sigma) following the manufacturers protocol.
The remaining halves of the scaffolds were incubated with the
fresh prepared alkaline dye for 30 minutes, aer which the
scaffolds were washed with demineralized water and imaged
with a Nikon stereomicroscope.
Scanning electron microscopy (SEM)
Formalin xated scaffold samples were dehydrated through an
ethanol series. The samples were immersed in HMDS (Sigma)
for 15 minutes aer total dehydration. Excessive HMDS was
removed and the samples were le to dry overnight. The dried
samples were mounted on a stage, gold sputtered and imaged
with a SEM (XL-30 ESEM-FEG, Phillips).
Statistical analysis
A two way ANOVA with Bonferroni's post-hoc test was used. P
values less than 0.05 were considered to be statistically signicant.
All values are reported as average mean with standard deviation.
Results
Mechanical characterization
Two types of PCL were chosen based on their molecular weight.
Compression moulded cylindrical blocks were subjected to an
unconned compression. The determined stiffness was 204.2
8.6 MPa for high PCL and 146.5  7.6 MPa for low PCL.54512 | RSC Adv., 2015, 5, 54510–54516Scaffold characterization
3D PCL scaffolds with pre-dened architectures were obtained
through additive manufacturing. Measurements showed an actual
ber spacing of 1068 23 mm, aber diameter of 213 26 mmand
a layer height of 159  14 mm for low PCL scaffolds. For high PCL
scaffolds, the ber spacing was 1059  22 mm, the ber diameter
was 187  18 mm and the layer thickness was 151  7 mm.
Cell distribution and ECM formation
Methylene blue images showed good cell attachment for both
low and high PCL and for all media (Fig. 1). Cell seeded scaf-
folds cultured in chondrogenic differentiation media showed
rounded cell morphology (Fig. 1M–R). Homogeneous cell
distribution was seen at each time point and SEM images
showed ECM deposition on the interior of the scaffold (Fig. 2).
DNA content between low and high PCL were similar (Fig. 3A).
Cell differentiation on low and high PCL
ALP/DNA showed higher values for samples cultured in chon-
drogenic medium as opposed to osteogenic differentiationThis journal is © The Royal Society of Chemistry 2015
Fig. 2 SEM images hMSC cultured on high PCL (A–C, G–I and M–O)
and low PCL (D–F, J–L and P–R) scaffolds in basic (A–F), osteogenic
(G–L) and chondrogenic (M–R) differentiation medium (scale bar is
200 mm).
Fig. 3 DNA (A), ALP/DNA (B) and GAG/DNA (C) for hMSC cultured on
low and high PCL scaffolds cultured in basic, osteogenic and chon-
drogenic differentiation medium (X is statistical significant difference
from day 7 in samemedia, + is statistical significant difference from day
14 in same media, o is statistical significant difference from high PCL
chondro at same timepoint/statistical significant difference from low































































































View Article Onlinemedium (Fig. 3B). It is only in chondrogenic media that the
ALP/DNA values signicantly increased in time for both PCL
scaffolds. In high PCL scaffolds, aer 28 days the ALP/DNA was
statistically signicant different between chondrogenic and
osteogenic differentiation media. For low PCL scaffolds the
results between chondrogenic and osteogenic differentiation
media were statistically signicant for day 14 and 28. The
ALP/DNA results showed statistically signicant higher values
for low PCL scaffolds for chondrogenic differentiation media at
day 14 and 28 compared to high PCL scaffolds. For cell seeded
scaffolds cultured in osteogenic differentiation media, there
was no statistically signicant difference between high PCL and
low PCL. The ALP staining corroborated the results of the
biochemical analysis (Fig. 4). The trend seen in the biochemical
analysis for basic media was reected in the staining, with a
peak at day 14. For cell seeded scaffolds cultured in osteogenic
and chondrogenic differentiation media, the staining became
more intense for day 14 and 28.
Chondrogenic differentiation was assessed by GAG produc-
tion (Fig. 3C). GAG production was shown to increase statisti-
cally signicant in time for cell seeded scaffolds cultured in
chondrogenic differentiation media. Both low and high PCL
supported chondrogenic differentiation as was also seen in the
methylene blue images through the rounded cell morphologyThis journal is © The Royal Society of Chemistry 2015(Fig. 1M–R). GAG/DNA increased from 6.89  0.78 mg GAG/mg
DNA at day 7 to 14.01  1.62 mg GAG/mg DNA at day 14, to a
maximum of 24.99  4.38 mg GAG/mg DNA at day 28 for high
PCL scaffolds. Similar results were seen for low PCL scaffolds
with 6.30 0.38 mg GAG/mg DNA at day 7, 9.98 3.59 mg GAG/mg
DNA at day 14, and a maximum of 23.55  5.24 mg GAG/mg DNA
at day 28 as well. There was no statistical signicant difference
between low and high PCL scaffolds. The GAG/DNA values for
scaffolds cultured in chondrogenic media were statistically
signicant higher than scaffolds cultured in basic and osteo-
genic media for day 14 and 28.Discussion
Using a temporary or permanent structure, a scaffold, is one of
the several strategies that exist to treat bone, chondral or
osteochondral defects. The biomaterial for fabricating aRSC Adv., 2015, 5, 54510–54516 | 54513
Fig. 4 ALP staining of hMSC cultured on high PCL (A–C, G–I and
M–O) and low PCL (D–F, J–L and P–R) scaffolds in basic (A–F),
osteogenic (G–L) and chondrogenic (M–R) differentiation medium































































































View Article Onlinescaffold can be either natural or synthetic. While ceramic and
natural polymers can elicit a cellular response, synthetic poly-
mers generally cannot do so.5,9,10 The tunable degradation time,
degradation products and FDA approval for specic medical
applications makes PCL an oen used polymer.15,26–28 PCL is
therefore available in a large number of different molecular
weights. Engler and Discher among others,19,20 have shown with
2D hydrogels, coated with collagen, that cells were able to sense
the stiffness of the hydrogel and determined their cell fate
accordingly. Huebsch et al. showed this in 2D,21 but also in 3D
hydrogels by encapsulating cells in alginate.22 By changing the
molecular weight of PCL, the surface chemistry and topography
remains the same but the bulk material stiffness will be
different. Using AM scaffolds of PCL, the cells experience a
different environment as they are not encapsulated and
restricted in a certainmorphology as they would in a hydrogel in
absence of adhesive domains. We therefore investigated if the
different molecular weight of PCL had an inuence on cell
behaviour in 3D scaffolds fabricated with similar structural
properties, surface chemistry and topography but different bulk54514 | RSC Adv., 2015, 5, 54510–54516stiffness. Solid cylindrical samples were punched from
compression moulded blocks and mechanically tested in an
unconned compression test. High PCL of 65.000 Da was stiffer
than low PCL of 14.000 Da and thus showed a different bulk
material stiffness with different molecular weights.
Methylene blue images of cell seeded scaffolds cultured in
chondrogenic differentiation media, showed a rounded cell
morphology suggesting the hMSCs differentiated towards the
chondrogenic lineage (Fig. 1M–R). Biochemical analysis for
chondrogenic differentiation showed a statistically signicant
increase in GAG/DNA in time for both low and high PCL
(Fig. 3C). However, there was no statistical signicant difference
for the GAG/DNA levels between low and high PCL. The levels of
GAG/DNA were higher than what reported in literature for in
vitro cultured chondrogenically induced hMSCs. For an osteo-
chondral scaffolds consisting of a PLA scaffold press coated
with a chondrifying cell pellet,29 as well as for electrospun
scaffolds seeded with hMSCs,30 a level around 5 mg GAG/mg DNA
was reported.
ALP activity was performed as this is one of the many factors
for the indication of hMSCs osteogenic differentiation (Fig. 3B).
Previous work showed higher ALP/DNA values for cell seeded
scaffolds cultured in chondrogenic differentiation medium
compared to osteogenic differentiation medium.31 In the pre-
sented study, the ALP/DNA levels were again statistically higher
for chondrogenic than osteogenic differentiation and basic
medium. Interestingly, ALP/DNA was statistically signicant
higher for cell seeded scaffolds cultured in chondrogenic
medium from low PCL compared to the osteogenic medium
from low PCL and compared to the chondrogenic and osteo-
genic cultured cell seeded scaffolds from high PCL. ALP stain-
ing corroborated the biochemical analysis (Fig. 4). Together,
these ndings could implicate that the hMSCs induced to
chondrogenic differentiation are going towards hypertrophy.
From literature, it is known that hMSCs do have the tendency to
differentiate towards a hypertrophic chondrogenic pheno-
type.32,33 Jeong and Hollister34 had similar results with PCL
scaffolds. However, they used chondrocytes and osteoblasts in
their study. Although this effect has been seen in previous
studies32,33 and our own work (submitted), further analysis
needs to be performed to further clarify if hMSCs induced to the
chondrogenic lineage are indeed going towards an hypertrophic
phenotype.
Additionally, the effect of bulk material stiffness on cell
behaviour in a 3D open porous structure could be investigated.
With AM the scaffold architecture was completely controlled.
Roosa et al.35 showed with PCL scaffolds that a pore size in the
range of 350–800 mm resulted in differences in bone regenera-
tion and mechanical properties aer 4 weeks of subcutaneous
implantation in mice. However, no benecial effects were
detectable anymore aer implantation for 8 weeks, even though
the porosity of the PCL scaffolds used were not the same. Hsu
et al.11 created scaffolds with a pore size of 250 mm through
fused deposition modelling. They changed the angle between
successive layers, effectively changing the pore shape. Addi-
tionally, they made square scaffolds and scaffolds which were































































































View Article Onlineresult in different cellular responses, but the concentric scaf-
folds showed more collagen deposition by the seeded
osteoblasts.
By using AM we could additionally investigate if the bulk
material stiffness had an inuence in 3D open porous scaffolds.
It is known that encapsulated cells in hydrogels do react to
stiffness. Yet, no study has investigated if this is also the case for
open porous 3D scaffolds. Changing the bulk stiffness could be
easily performed by using a different polymer. This will,
however, result in a different surface chemistry and topography
as well, which are biomaterial characteristics known to have the
ability to inuence cell behaviour.36,37 Using the same polymer,
PCL, but different molecular weights, the bulk stiffness was
changed maintaining surface chemistry and topography
unaltered.
Most reported studies that investigate the inuence of
biomaterial stiffness on cell differentiation were conducted
with hydrogels.19–23 The stiffness range for instructing differ-
entiation was reported to be in the range of 1–100 kPa for 2D
hydrogels coated with collagen and 3D hydrogels where cells
were encapsulated. In our situation the stiffness of the bulk
material far exceeds the stiffness of the hydrogels. Another
fundamental difference is that cells were not encapsulated but
attached to the scaffold surface. The deposited ECM accu-
mulates over time creating a distance from the surface of the
scaffold. It is known that cells can sense up to a certain
distance the stiffness, which would be at some point in time
the stiffness of the deposited ECM.38,39 As demonstrated by
Chaudhuri et al.21 not only the stiffness of the material is
important but also the ligand density, the cell-ECM anchoring.
They showed that the available ligand density and the oppor-
tunity for cells to actively remodel their environment were also
able to direct cell differentiation. In our 3D AM scaffolds, the
ECM secreted by the cells can be remodelled without restric-
tions imposed by the scaffold system, in contrast to cells
encapsulated in hydrogels.
Scaffolds were coated with collagen type I before cell
seeding. This means that cells were not directly interacting
with the PCL surface, which may inuence the actual surface
stiffness that is perceived by the cells. However, Trappmann
et al.40 reported that the stiffness as sensed by cells mainly
depends on the protein–biomaterial surface interactions. With
more binding sites between the protein and the surface, less
deformation of the protein is possible and cells sense a higher
stiffness of the biomaterial surface. Less binding sites between
surface and proteins result in cells perceiving a lower stiffness.
In this study, by using the same polymer with different
molecular weights, the same surface chemistry and therefore
the same surface–protein interaction can be expected. As such,
the inuence of different surface–protein interaction should
not play a signicant role, and differences in the stiffness
perceived by the cells will be based on differences in stiffness
of the biomaterial.
The cells seeded on low PCL had a statistically signicant
higher ALP/DNA level than high PCL. Currently, the mechanism
that causes the observed difference is not known. More research
should be conducted to unravel the cause of the underlyingThis journal is © The Royal Society of Chemistry 2015mechanism responsible for the higher ALP/DNA levels. To
assess the chondrogenic and osteogenic differentiation of the
hMSCs, the common markers GAG and ALP were measured. In
future experiments, PCR and immunohistological staining
should be performed to further discriminate between the
differentiation lineages and between the low and high PCL
scaffolds. For osteogenic differentiation bone sialoprotein,
BMP2, osteocalcin, osteopontin and osteonectin would be good
markers, while for chondrogenic differentiation collagen type-
II, collagen type-X, SOX-9, and aggrecan would be logical
choices. Collagen type-X could give indication if the chondro-
genic differentiation is indeed going towards hypertrophy as
expected by the high GAG/DNA coupled with the high ALP/DNA
ratio. Performing long term cultures (e.g. 8 weeks) should
indicate if the current observations will be sustained on a longer
time period. It would be interesting to investigate if a molecular
weight of PCL higher than 65.000 Da would result in lower
ALP/DNA values and what would be the cause of this phenom-
enon. The difference in bulk mechanical stiffness by using a
different molecular weight could be very useful in designing
scaffolds. The relation between pore size, shape and porosity on
the apparent stiffness of the scaffold is described in litera-
ture.41–43 Pore structural properties could be, therefore, an extra
variable available to customize the scaffold design to meet the
desired criteria, for example matching scaffold mechanical
properties to the native tissue mechanical properties. The effect
of bulk stiffness and scaffold architecture could be used in a
mechanically loading bioreactor, for example, to optimize and
precondition tissue engineering scaffolds. The design of the
scaffold could be further optimized by coupling such mechan-
ical loading with numerical modelling able to predict cell
differentiation.24Conclusions
Two extremes of molecular weights for PCL were chosen, 14.000
Da and 65.000 Da. Mechanical analysis showed a higher stiff-
ness for the high molecular weight PCL. Cell seeded scaffolds of
low and high PCL were cultured in basic, osteogenic and
chondrogenic differentiation medium. In both low and high
PCL the GAG/DNA levels were high, showing a robust chon-
drogenic differentiation. Interestingly, low PCL had higher
levels of ALP/DNA than high PCL suggesting a stronger
tendency for low PCL to go into hypertrophy. Further research
should aim at unravelling the cause for this phenomenon as the
results could be used to design site specic regions in an
osteochondral scaffold.Acknowledgements
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